Experience of long-term treatment with tiotropium bromide of patients with chronic obstructive pulmonary disease
https://doi.org/10.18093/0869-0189-2007-0-2-74-78
Abstract
This one-year open randomized comparative trial was designed to evaluate efficacy of tiotropium bromide (TB) in disabled patients with mild to moderate chronic obstructive pulmonary disease (COPD). The patients were Ј 60 years old. The TB group patients (n = 46) received Spiriva (Boehringer Ingelheim, Germany) 18 mg daily, the F group patients (n = 29) received Foradil (Novartis Pharma AG, Switzerland) 12 mg b.i.d. for a year. The active control group (AC, n = 14) were given inhaled steroids and short-acting b2-agonists as before entering the trial. We assessed lung function using spirometry, the annual decline of FEV1, severity of dyspnea using Baseline and Transitional Dyspnea Indexes, rate and length of exacerbations, and quality of life (QoL) using the St.George's Respiratory Questionnaire. The trial was close to real-life practice. Results demonstrated efficacy of both TB and F in therapy of disabled COPD patients compared with the AC group. Criteria of efficacy of long-term TB administration were slowing of the annual FEV1 decline, improvement of dyspnea, reduction in number of exacerbations, and improvement of QoL in TB and F patients compared with the baseline.
About the Authors
V. A. Ignatiev
НИИП СПБГМУ им. акад. И.П.Павлова
Russian Federation
Russian Federation
O. N. Titova
НИИП СПБГМУ им. акад. И.П.Павлова
Russian Federation
Russian Federation
M. A. Kameneva
НИИП СПБГМУ им. акад. И.П.Павлова
Russian Federation
Russian Federation
O. A. Sukhovskaya
НИИП СПБГМУ им. акад. И.П.Павлова
Russian Federation
Russian Federation
References
1. Авдеев С.Н. Роль тиотропия в терапии больных хронической обструктивной болезнью легких: новые данные (по материалам 14-го конгресса Европейского респираторного общества, Глазго 2004). Consilium Medicum 2004. 10: 475–480.
2. Калманова Е.Н., Айсанов З.П. Форадил в терапии ХОБЛ: результаты клинических исследований. Пульмонология 2003; 5: 115–122.
3. Чучалин А.Г. (ред.) Хроническая обструктивная болезнь легких. Практическое руководство для врачей. (Федеральная программа. 2-е изд.). М.; 2004. 1–61.
4. Brusasco V., van Noord J.A., Greefhorst A.P.M. et al. Health outcomes in 6-month placebo-controlled trial of once-daily tiotropium compared with twice-daily salmeterol in patients with COPD. Thorax 2003; 58: 47–55.
5. Bubling F., Lieder N., Welte T. Anti-inflammatory function of tiotropium mediated by suppression of acetylcholineinduced release of chemotactic activity. Eur. Respir. J. 2004; 24 (suppl. 48): 318, abstr. 2024.
6. Decramer M., Celli B., Tashkin D.P. et al. Clinical trial design considerations in assessing long-term functional impacts in COPD: the Uplift trial. J. Chron. Obstruct. Pulm. Dis. 2004; 1: 303–312.
7. Global Initiative for Chronic Obstructive Lung Diseases (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Publication Number 2701, April 2001: 1–100. Updated 2003. GOLD website (www.goldcopd.com). Accessed 2 December 2004
8. Jones P.W. Interpreting thresholds for clinically significant change in health status in asthma and COPD. Eur. Respir. J. 2002; 19: 398–404.
9. Mahler D.A., Weinberg D.H., Wells C.K. et al. Baseline dyspnea index and transitional index: the measurement of dyspnea. Chest 1984. 85: 751–758.
10. Noord J.A., Aumann J. l., Janssens E. et al. Comparison of titropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur. Respir. J. 2005; 26: 214–222.
11. Rossi A., Kristufek P.I., Levine B.E. et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 121: 1058–1069.
12. Tashkin D.P., Cooper C.B. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004; 125: 249–251.
13. Tashkin D.P., Detels R., Simmons M. et al. The UCLA population studies of chronic obstructive respiratory disease: XІ. Impact of air pollution and smoking on annual change in forced expiratory volume in one second. Am. J. Respir. Crit. Care Med. 1994; 149: 1209–1217.
14. Vinckin W., van Noord J.A., Greefhorst A.P.M. et al. Improved health outcomes in patients with COPD during 1-year treatment with tiotropium. Eur. Respir. J. 2002; 19: 209–216.
15. Zu Wallack R. Clinical interpretation of health-related quality of life outcomes in chronic obstructive pulmonary disease. Eur. Respir. Rev. 2002; 12: 65–66.
Review
For citations:
Ignatiev V.A., Titova O.N., Kameneva M.A., Sukhovskaya O.A. Experience of long-term treatment with tiotropium bromide of patients with chronic obstructive pulmonary disease. PULMONOLOGIYA. 2007;(2):74-78. (In Russ.) https://doi.org/10.18093/0869-0189-2007-0-2-74-78
Views:
249
Email this article 